Table 4. Logistic regression analyses of hepatic decompensation in patients with liver cirrhosis.

	Univariate analysis		Multivariate analysis
	P-value	OR (95% CI)	P-value	OR (95% CI)
Entire Cohort
Male gender	0.92	0.97 (0.51–1.83)
Age	0.4	1.01 (0.98–1.04)
Coffee, cups per day	0.000003	0.36 (0.23–0.55)	0.0002	0.33 (0.18–0.59)
Presence of diabetes	0.004	2.64 (1.37–5.10)	0.001	4.62 (1.86–11.55)
MELD score	<0.00001	1.22 (1.14–1.32)	0.0004	1.20 (1.08–1.32)
Leukocytes / nl	0.2	0.91 (0.79–1.06)
Hemoglobin (g/dL)	<0.00001	0.62 (0.53–0.73)	0.0004	0.71 (0.59–0.86)
25(OH)D3 <10ng/mL	0.01	2.44 (1.22–4.76)	0.01	3.25 (1.30–8.20)
Presence/history of ascites	0.00001	4.7 (2.36–9.65)
Subgroup of patients with vitamin D supplementation
Male gender	0.7	0.78 (0.23–2.61)
Age	0.3	0.92 (0.97–1.02)
Coffee, cups per day	0.02	0.11 (0.02–0.75)	0.04	0.11 (0.01–0.92)
Presence of diabetes	0.3	1.90 (0.51–7.03)
MELD score	0.0008	1.24 (1.09–1.41)	0.05	1.16 (1.00–1.35)
Leukocytes / nl	0.2	0.58 (0.59–1.12)
Hemoglobin (g/dL)	0.003	0.58 (0.41–0.83)
25(OH)D3 <10ng/mL	0.9	0.41 (0.01–9.88)
Presence/history of ascites	0.01	13.5 (1.65–111)
Subgroup of patients without vitamin D supplementation
Age	0.1	1.02 (0.97–1.08)
Coffee, cups per day	0.0001	0.41 (0.14–0.82)	0.003	0.36 (0.19–0.71)
Presence of diabetes	0.006	2.92 (1.35–6.32)	0.006	4.72 (1.56–14.3)
MELD score	0.00001	1.21 (1.11–1.33)	0.007	1.18 (1.04–1.34)
Leukocytes / nl	0.5	0.95 (0.80–1.12)
Hemoglobin (g/dL)	<0.00001	0.63 (0.52–0.75)	0.002	0.70 (0.56–0.88)
25(OH)D3 <10ng/mL	0.02	2.43 (1.14–5.00)	0.04	3.03 (1.06–9.01)
Presence/history of ascites	0.003	4.29 (1.94–9.44)

MELD, model of end-stage liver disease.